Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Evandro de Azambuja

Showing results (231-240 of 259) with videos related to

Pageof 26
Sort By:
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 20, 2023
Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO)Orit Kaidar-Person, Icro Meattini, Liesbeth J Boersma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Multifactorial approach to predicting resistance to anthracyclinesChristine Desmedt, Angelo Di Leo, Evandro de Azambuja, et al.
Lancet (London, England)|July 23, 2013
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trialAron Goldhirsch, Richard D Gelber, Martine J Piccart-Gebhart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2023
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 TherapyPierre Squifflet, Everardo D Saad, Sibylle Loibl, et al.
Lancet (London, England)|January 20, 2012
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trialJosé Baselga, Ian Bradbury, Holger Eidtmann, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 12, 2023
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast CancerMatteo Lambertini, Marcello Ceppi, Richard A Anderson, et al.
Eclinicalmedicine|May 31, 2023
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studiesMatteo Lambertini, Eva Blondeaux, Giancarlo Bisagni, et al.
European Journal of Cancer (Oxford, England : 1990)|August 13, 2023
Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancerKaren Van Baelen, Ha-Linh Nguyen, Anne-Sophie Hamy-Petit, et al.
Breast Cancer Research and Treatment|July 10, 2026
EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN studyDiogo Martins-Branco, Soraia Lobo-Martins, Philippe Aftimos, et al.
The Lancet. Oncology|August 19, 2014
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete responseEvandro de Azambuja, Andrew P Holmes, Martine Piccart-Gebhart, et al.
Pageof 26

Showing results (231-240 of 259) with videos related to

Sort By:
Pageof 26
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|December 20, 2023
Essential requirements for reporting radiation therapy in breast cancer clinical trials: An international multi-disciplinary consensus endorsed by the European Society for Radiotherapy and Oncology (ESTRO)Orit Kaidar-Person, Icro Meattini, Liesbeth J Boersma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 23, 2011
Multifactorial approach to predicting resistance to anthracyclinesChristine Desmedt, Angelo Di Leo, Evandro de Azambuja, et al.
Lancet (London, England)|July 23, 2013
2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trialAron Goldhirsch, Richard D Gelber, Martine J Piccart-Gebhart, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 28, 2023
Re-Evaluation of Pathologic Complete Response as a Surrogate for Event-Free and Overall Survival in Human Epidermal Growth Factor Receptor 2-Positive, Early Breast Cancer Treated With Neoadjuvant Therapy Including Anti-Human Epidermal Growth Factor Receptor 2 TherapyPierre Squifflet, Everardo D Saad, Sibylle Loibl, et al.
Lancet (London, England)|January 20, 2012
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trialJosé Baselga, Ian Bradbury, Holger Eidtmann, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|January 12, 2023
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast CancerMatteo Lambertini, Marcello Ceppi, Richard A Anderson, et al.
Eclinicalmedicine|May 31, 2023
Prognostic and clinical impact of the endocrine resistance/sensitivity classification according to international consensus guidelines for advanced breast cancer: an individual patient-level analysis from the Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) studiesMatteo Lambertini, Eva Blondeaux, Giancarlo Bisagni, et al.
European Journal of Cancer (Oxford, England : 1990)|August 13, 2023
Association of body mass index with clinicopathological features and survival in patients with primary invasive lobular breast cancerKaren Van Baelen, Ha-Linh Nguyen, Anne-Sophie Hamy-Petit, et al.
Breast Cancer Research and Treatment|July 10, 2026
EVERolimus effectiveness after proGREssion on ENdocrine therapy plus CDK4/6 inhibitor for ER-positive/HER2-negative advanced breast cancer: EVERGREEN studyDiogo Martins-Branco, Soraia Lobo-Martins, Philippe Aftimos, et al.
The Lancet. Oncology|August 19, 2014
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete responseEvandro de Azambuja, Andrew P Holmes, Martine Piccart-Gebhart, et al.
Pageof 26